Posts made in February, 2012

New Prostate Cancer treatment for New Zealand

Posted by on 19 Feb 2012 in News | 0 comments

Thanks to the results of one of the prostate cancer trials Canterbury Urology Research Trust have been involved in, the U.S. Food and Drug Administration (FDA) has approved a new drug, Denosumab for use in prevention of skeletal-related events in patients with bone metastases. This makes Denosumab the first RANKL inhibitor to be approved by the FDA, and is now available for use in New Zealand.

Read More